BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21389866)

  • 1. Combinational therapy of interferon-α and chemotherapy normalizes tumor vasculature by regulating pericytes including the novel marker RGS5 in melanoma.
    Liu P; Zhang C; Chen J; Zhang R; Ren J; Huang Y; Zhu F; Li Z; Wu G
    J Immunother; 2011 Apr; 34(3):320-6. PubMed ID: 21389866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma.
    Zhu Y; Tibensky I; Schmidt J; Hackert T; Ryschich E; Jäger D; Büchler MW; Märten A
    J Immunother; 2008 Jan; 31(1):28-33. PubMed ID: 18157009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular normalization in Rgs5-deficient tumours promotes immune destruction.
    Hamzah J; Jugold M; Kiessling F; Rigby P; Manzur M; Marti HH; Rabie T; Kaden S; Gröne HJ; Hämmerling GJ; Arnold B; Ganss R
    Nature; 2008 May; 453(7193):410-4. PubMed ID: 18418378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy of human pancreatic cancer implanted in nude mice by oral fluoropyrimidine anticancer agent (S-1) with interferon-alpha.
    Miyake K; Tsuchida K; Sugino H; Imura S; Morine Y; Fujii M; Shimada M
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):113-26. PubMed ID: 16699793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
    Baker DP; Lin EY; Lin K; Pellegrini M; Petter RC; Chen LL; Arduini RM; Brickelmaier M; Wen D; Hess DM; Chen L; Grant D; Whitty A; Gill A; Lindner DJ; Pepinsky RB
    Bioconjug Chem; 2006; 17(1):179-88. PubMed ID: 16417267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature.
    Fenton BM; Paoni SF
    Cancer Res; 2007 Oct; 67(20):9921-8. PubMed ID: 17942924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins.
    Wada H; Nagano H; Yamamoto H; Arai I; Ota H; Nakamura M; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Doki Y; Dono K; Nakamori S; Sakon M; Monden M
    Oncol Rep; 2007 Oct; 18(4):801-9. PubMed ID: 17786339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RGS5 expression is a quantitative measure of pericyte coverage of blood vessels.
    Mitchell TS; Bradley J; Robinson GS; Shima DT; Ng YS
    Angiogenesis; 2008; 11(2):141-51. PubMed ID: 18038251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels.
    Iivanainen E; Lauttia S; Zhang N; Tvorogov D; Kulmala J; Grenman R; Salven P; Elenius K
    Microvasc Res; 2009 Dec; 78(3):278-85. PubMed ID: 19596357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulator of G protein signaling 5: a new player in vascular remodeling.
    Manzur M; Ganss R
    Trends Cardiovasc Med; 2009 Jan; 19(1):26-30. PubMed ID: 19467451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade.
    Nisancioglu MH; Betsholtz C; Genové G
    Cancer Res; 2010 Jun; 70(12):5109-15. PubMed ID: 20501841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent.
    Sochanik A; Mitrus I; Smolarczyk R; Cichoń T; Snietura M; Czaja M; Szala S
    Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):235-45. PubMed ID: 20383751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis.
    Guan YY; Luan X; Xu JR; Liu YR; Lu Q; Wang C; Liu HJ; Gao YG; Chen HZ; Fang C
    Biomaterials; 2014 Mar; 35(9):3060-70. PubMed ID: 24393268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis.
    Gautam A; Densmore CL; Melton S; Golunski E; Waldrep JC
    Cancer Gene Ther; 2002 Jan; 9(1):28-36. PubMed ID: 11916242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects.
    Sundstedt A; Celander M; Hedlund G
    Int Immunopharmacol; 2008 Mar; 8(3):442-52. PubMed ID: 18279798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gold(III) porphyrin 1a prolongs the survival of melanoma-bearing mice and inhibits angiogenesis.
    Lum CT; Huo L; Sun RW; Li M; Kung HF; Che CM; Lin MC
    Acta Oncol; 2011 Jun; 50(5):719-26. PubMed ID: 21110776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
    Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
    Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
    Hasumi Y; Kłosowska-Wardega A; Furuhashi M; Ostman A; Heldin CH; Hellberg C
    Int J Cancer; 2007 Dec; 121(12):2606-14. PubMed ID: 17691110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of murine alpha-, beta-, and gamma-interferons in combination with alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, on the tumor growth and metastasis of B16 melanoma and Lewis lung carcinoma in mice.
    Sunkara PS; Bowlin TL; Rosenberger AL; Fleischmann WR
    J Biol Response Mod; 1989 Apr; 8(2):170-9. PubMed ID: 2499664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.